Global Allogeneic Cell Therapy Market Size, Trends & Growth Opportunity, By Therapy Type (Stem Cell Therapies, Non-stem Cell Therapies), By Therapeutic Area (Hematological Disorders, Dermatological Disorders, Others), By Region and Forecast till 2030.
Global Allogeneic Cell Therapy Market.
The global Allogeneic Cell Therapy market was valued at USD 878.22 million in 2022 which expected to reach USD 3428.45 million by 2030 at a CAGR 18.52% from 2023-2030.
A process when a patient obtains healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been lost due to radiation or high-dose chemotherapy treatment.
Market Drivers
The industry for allogeneic cell treatment is anticipated to expand as a result of the rising prevalence of chronic diseases such cancer, cardiovascular disease, autoimmune disorders, and genetic diseases. The American Cancer Society calculated that 1.9 million new cancer cases would be diagnosed in the United States alone in 2022, resulting in more than 609,000 fatalities. Also, it is anticipated that the ageing population would contribute to an increase in the burden of chronic diseases on a global scale. These elements highlight the urgent requirement for cutting-edge medical procedures, such allogeneic cell therapy, to cure chronic illnesses and enhance patient outcomes.
Impact of COVID-19
The allogeneic cell treatment market was negatively impacted by the COVID-19 pandemic, which resulted in a decrease in R&D activities. This caused a number of processes to become sluggish, including manufacturing, logistics, clinical trials, research, and clinical evidence for cell and gene therapies. Evaluation of the therapeutic advantages and financial effects of these medicines has been harder as a result. The epidemic has also increased awareness of cell therapy as a possible COVID-19 therapeutic option. In the upcoming years, it is anticipated that this growing awareness will benefit the market.
Market Segmentation
The Global Allogeneic Cell Therapy Market is segmented into Therapy Type, Therapeutic Area. By Therapy Type such as Stem Cell Therapies, Non-stem Cell Therapies. Further, market is segmented into By Therapeutic Area such as Hematological Disorders, Dermatological Disorders, Others.
Regional Analysis
Global Allogeneic Cell Therapy Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the market. The region has a huge need for cutting-edge medical therapies, particularly cell-based therapies, to treat chronic illnesses, which is fueling market expansion. In addition, the area is home to a number of biotechnology firms, research centers, and academic institutions engaged in the creation and evaluation of novel allogeneic cell-based therapies.
These organizations are able to carry out considerable research and development operations because of the significant funding they receive from both the public and commercial sectors.
Key Players
Various key players are listed in this report such as LifeSouth Community Blood Centers, Inc., JCR Pharmaceuticals Co., Ltd, Sumitomo Pharma Co., Ltd., Atara Biotherapeutics, Mallinckrodt Pharmaceuticals, Tego Science Inc, Takeda Pharmaceutical Company Limited, Stempeutics Research Pvt Ltd, Biosolution Co., Ltd., MEDIPOST Co., Ltd
Market Taxonomy
By Therapy Type
• Stem Cell Therapies
o Hematopoietic Stem Cell Therapies
o Mesenchymal Stem Cell Therapies
• Non-stem Cell Therapies
o Keratinocytes & Fibroblast-based Therapies
o Others
By Therapeutic Area
• Hematological Disorders
• Dermatological Disorders
• Others
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa
Key Questions Addressed by the Report
• What are the Key Opportunities in Global Allogeneic Cell Therapy Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
Global Allogeneic Cell Therapy Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Allogeneic Cell Therapy Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Allogeneic Cell Therapy Market, By Therapy Type
5.1 Y-o-Y Growth Comparison, By Therapy Type
5.2 Global Allogeneic Cell Therapy Market Share Analysis, By Therapy Type
5.3 Global Allogeneic Cell Therapy Market Size and Forecast, By Therapy Type
5.3.1 Stem Cell Therapies
5.3.1.1 Hematopoietic Stem Cell Therapies
5.3.1.2 Mesenchymal Stem Cell Therapies
5.3.2 Non-stem Cell Therapies
5.3.2.1 Keratinocytes & Fibroblast-based Therapies
5.3.2.2 Others
6 Global Allogeneic Cell Therapy Market, By Therapeutic Area
6.1 Y-o-Y Growth Comparison, By Therapeutic Area
6.2 Global Allogeneic Cell Therapy Market Share Analysis, By Therapeutic Area
6.3 Global Allogeneic Cell Therapy Market Size and Forecast, By Therapeutic Area
6.3. 1 Hematological Disorders
6.3.2 Dermatological Disorders
6.3.3 Others
7 Global Allogeneic Cell Therapy Market, By Region
7.1 Global Allogeneic Cell Therapy Market Share Analysis, By Region
7.2 Global Allogeneic Cell Therapy Market Share Analysis, By Region
7.3 Global Allogeneic Cell Therapy Market Size and Forecast, By Region
8 North America Allogeneic Cell Therapy Market Analysis and Forecast (2023-2030)
8.1 Introduction
8.2 North America Allogeneic Cell Therapy Market Share Analysis, By Therapy Type
8.3 North America Allogeneic Cell Therapy Market Size and Forecast, By Therapeutic Area
8.4 North America Allogeneic Cell Therapy Market Size and Forecast, By Country
8.5.1 U.S.
8.6.2 Canada
9.7.3 Mexico
9 Europe Allogeneic Cell Therapy Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 Europe Allogeneic Cell Therapy Market Share Analysis, By Therapy Type
9.3 Europe Allogeneic Cell Therapy Market Size and Forecast, By Therapeutic Area
9.4 Europe Allogeneic Cell Therapy Market Size and Forecast, By Country
9.5.1 Germany
9.6.2 France
9.7.3 UK
9.8.4. Rest of Europe
10 Asia Pacific Allogeneic Cell Therapy Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Asia Pacific Allogeneic Cell Therapy Market Share Analysis, By Therapy Type
10.3 Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, By Therapeutic Area
10.4 Asia Pacific Allogeneic Cell Therapy Market Size and Forecast, By Country
10.5.1 China
10.6.2 Japan
10.7.3 India
10.8.4. Rest of Asia Pacific
11 Latin America Allogeneic Cell Therapy Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Latin America Allogeneic Cell Therapy Market Share Analysis, By Therapy Type
11.3 Latin America Allogeneic Cell Therapy Market Size and Forecast, By Therapeutic Area
11.4 Latin America Allogeneic Cell Therapy Market Size and Forecast, Country
11.5.1. Brazil
11.6.2. Rest of Latin America
12 Middle East Allogeneic Cell Therapy Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Middle East Allogeneic Cell Therapy Market Share Analysis, By Therapy Type
12.3 Middle East Allogeneic Cell Therapy Market Size and Forecast, By Therapeutic Area
12.4 Middle East Allogeneic Cell Therapy Market Size and Forecast, By Country
12.5.1. Saudi Arabia
12.6.2. UAE
12.7.3. Egypt
12.8.4. Kuwait
12.9.5. South Africa
13 Competitive Analysis
13.1 Competition Dashboard
13.2 Market share Analysis of Top Vendors
13.3 Key Development Strategies
14Company Profiles
14.1 LifeSouth Community Blood Centers, Inc.
14.1.1 Overview
14.1.2 Offerings
14.1.3 Key Financials
14.1.4 Business Segment & Geographic Overview
14.1.5 Key Market Developments
14.1.6 Key Strategies
14.2. JCR Pharmaceuticals Co., Ltd.
14.2.1 Overview
14.2.2 Offerings
14.2.3 Key Financials
14.2.4 Business Segment & Geographic Overview
14.2.5 Key Market Developments
14.2.6 Key Strategies
14.3. Sumitomo Pharma Co., Ltd.
14.3.1 Overview
14.3.2 Offerings
14.3.3 Key Financials
14.3.4 Business Segment & Geographic Overview
14.3.5 Key Market Developments
14.3.6 Key Strategies
14.4 Atara Biotherapeutics
14.4.1 Overview
14.4.2 Offerings
14.4.3 Key Financials
14.4.4 Business Segment & Geographic Overview
14.4.5 Key Market Developments
14.4.6 Key Strategies
14.5 Mallinckrodt Pharmaceuticals
14.5.1 Overview
14.5.2 Offerings
14.5.3 Key Financials
14.5.4 Business Segment & Geographic Overview
14.5.5 Key Market Developments
14.5.6 Key Strategies
14.6 Tego Science Inc
14.6.1 Overview
14.6.2 Offerings
14.6.3 Key Financials
14.6.4 Business Segment & Geographic Overview
14.6.5 Key Market Developments
14.6.6 Key Strategies
14.7 Takeda Pharmaceutical Company Limited
14.7.1 Overview
14.7.2 Offerings
14.7.3 Key Financials
14.7.4 Business Segment & Geographic Overview
14.7.5 Key Market Developments
14.7.6 Key Strategies
14.8 Stempeutics Research Pvt Ltd
14.8.1 Overview
14.8.2 Offerings
